Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Tenenbaum

Showing results (11-20 of 116) with videos related to

Pageof 12
Sort By:
Cardiovascular Diabetology|June 25, 2014
Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?Enrique Z Fisman, Alexander Tenenbaum
Cardiovascular Diabetology|November 25, 2021
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospectEnrique Z Fisman, Alexander Tenenbaum
Cardiovascular Diabetology|September 30, 2015
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesEnrique Z Fisman, Alexander Tenenbaum
Cardiology Journal|April 23, 2014
Authors' responseEnrique Z Fisman, Alexander Tenenbaum
Advances in Cardiology|April 16, 2008
Cardiovascular diabetology: clinical, metabolic and inflammatory facets. PrefaceEnrique Z Fisman, Alexander Tenenbaum
Cardiovascular Diabetology|November 16, 2012
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?Alexander Tenenbaum, Enrique Z Fisman
Cardiovascular Diabetology|January 29, 2011
"The metabolic syndrome... is dead": these reports are an exaggerationAlexander Tenenbaum, Enrique Z Fisman
Cardiovascular Diabetology|July 21, 2017
Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner?Alexander Tenenbaum, Enrique Z Fisman
Cardiovascular Diabetology|December 3, 2004
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?Alexander Tenenbaum, Enrique Z Fisman
Cardiology Journal|August 6, 2013
Optimal revascularization in diabetes after the FREEDOM trial: were the controversies finally settled?Alexander Tenenbaum, Enrique Z Fisman
Pageof 12

Showing results (11-20 of 116) with videos related to

Sort By:
Pageof 12
Cardiovascular Diabetology|June 25, 2014
Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?Enrique Z Fisman, Alexander Tenenbaum
Cardiovascular Diabetology|November 25, 2021
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospectEnrique Z Fisman, Alexander Tenenbaum
Cardiovascular Diabetology|September 30, 2015
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesEnrique Z Fisman, Alexander Tenenbaum
Cardiology Journal|April 23, 2014
Authors' responseEnrique Z Fisman, Alexander Tenenbaum
Advances in Cardiology|April 16, 2008
Cardiovascular diabetology: clinical, metabolic and inflammatory facets. PrefaceEnrique Z Fisman, Alexander Tenenbaum
Cardiovascular Diabetology|November 16, 2012
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?Alexander Tenenbaum, Enrique Z Fisman
Cardiovascular Diabetology|January 29, 2011
"The metabolic syndrome... is dead": these reports are an exaggerationAlexander Tenenbaum, Enrique Z Fisman
Cardiovascular Diabetology|July 21, 2017
Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner?Alexander Tenenbaum, Enrique Z Fisman
Cardiovascular Diabetology|December 3, 2004
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?Alexander Tenenbaum, Enrique Z Fisman
Cardiology Journal|August 6, 2013
Optimal revascularization in diabetes after the FREEDOM trial: were the controversies finally settled?Alexander Tenenbaum, Enrique Z Fisman
Pageof 12